Type XVII collagen (COL17) and the non-collagenous 16A (NC16A) domain is regarded as the major pathogenic domains for bullous pemphigoid (BP). Some patients with BP have autoantibodies against parts of COL17 outside the NC16A domain (hereinafter the non-NC16A domain) and show less inflammatory manifestations. There were no significant differences in titres and IgG subclasses between NC16A-BP and non-NC16A-BP as determined by indirect immunofluorescent microscopy. The neutrophil activation capacities determined by ROS release did not differ between NC16A-BP and non-NC16A-BP.
| BACKGROUND
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease. The autoantibodies mainly target type XVII collagen (COL17), and the non-collagenous 16A (NC16A) domain is regarded as the major pathogenic domain for BP. [1] Autoantibodies against COL17-NC16A
can be detected in approximately 80% of patients with BP, and serum titres correlate with disease severity. [2] [3] [4] Recently, we developed a fulllength COL17 ELISA that can also detect approximately 80% of patients with BP. [5] Some patients with BP have autoantibodies against parts of COL17 outside the NC16A domain (hereinafter the non-NC16A domain), such as against the C-terminus. [6] Non-NC16A-BP is frequently associated with the oral medication history of dipeptidyl peptidase-4 inhibitor (DPP4-i) and present less inflammatory manifestations. [5] While the blistering relevance of autoantibodies against NC16A
has been well studied in BP, the pathogenicity of autoantibodies against the non-NC16A domain remains unclear. The precise mechanisms lead to find novel therapeutic targets, e.g protein kinase C or heat-shock protein 90. [7, 8] 
| QUESTIONS ADDRESSED
We investigate the BP pathomechanism in patients with autoantibodies against non-NC16A who presented mild clinical manifestations with less inflammation, using cell culture systems.
| EXPERIMENTAL DESIGN
Detailed methods are described in Data S1. Figure 1B ). Although there were some differences in ROS production, binding IgG to COL17 was also some differences ( Figure 1A ).
| RESULTS

| The titre level and
This reason was discussed in the Data S1.
| Non-NC16A-BP IgG had significantly less capacity to deplete COL17
When normal human epidermal keratinocytes (NHEKs) were treated with BP-IgG, BP-IgG caused the internalization of COL17 from the plasma membrane and depleted keratinocytes of COL17. [9] NC16A-BP IgG, but not non-NC16A-BP IgG, was found to deplete COL17 in a dose-dependent manner (Fig. S1A ,B, middle). α6 Integrins and β4-integrin were unaffected by the IgG stimulations (Fig. S1C ).
All cases of treatment with NC16A-BP IgG, but none of treatment with non-NC16A-BP IgG, demonstrated marked COL17 depletion capacity (Figure 2A,B) .
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| COL17A1 was overexpressed under NC16A-BP IgG stimulations
When NHEKs were treated with NC16A-BP IgG, COL17A1 were overexpressed ( Figure 2C ). This was confirmed in the organ-cultured skin as well (Fig. S1D ). 
| Non-NC16A-BP IgG barely weakened the adhesion strength
| CONCLUSIONS
The clinical manifestations of non-NC16A-BP, which presents mild clinical blistering and mild erythema, are distinct from those of typical BP, which shows tense blisters associated with erythema. [5] While the autoantibodies of mucous membrane pemphigoid (MMP) often target the C-terminus of COL17, the clinical manifestations of MMP are totally different from those of non-NC16A-BP. Several cases of DPP4-i-associated BP have been reported as non-NC16A-BP. [5, 10] The genetic associations are studied in autoimmune diseases, including F I G U R E 1 IgG from non-NC16A-BP and from NC16A-BP activates neutrophils in an ROS release assay. COL17 (500 ng/ well) was coated in 96-well white plates. To generate immune complexes, BP-IgG (2 mg/mL) or normal human IgG (2 mg/mL) was added. Subsequently, freshly isolated human neutrophils (100 μL×10 7 cells/mL) were added. (A), ROS production was measured and normalized by the negative control as 100%. (B), Representative chemiluminescence of activated neutrophils stimulated with sera, as detected by digital imager. (C), OD score using full-length COL17 ELISA. Experiments were performed using two healthy blood donors in duplicate. The y-axis indicates the relative density of chemiluminescence to negative control. The positive and negative controls were replaced with 0.1 μg/mL of PMA and PBS, respectively. Error bars indicate SEM. *P<0.05 BP. [11] [12] [13] In addition, some adverse drug reactions are strongly related to genetic background. [14] Hence, DPP4-i-induced BP may be related to some genetic backgrounds.
We reported the epitope-dependent pathogenicity of antibodies to COL17 [15] using in mouse [15] , and speculate that autoantibodies against different epitopes might have individual blistering mechanisms. Liu et al.
reported significant insights into complement activation in blistering mechanisms using a BP mouse model. [16] Although IgG3 is the most effective IgG subclass in achieving complement activation in human, previous reports demonstrated that either IgG1 or IgG4 is the predominant subclass in BP. [17] In our studies, IgG1 was found to be the predominant subclass in NC16A-BP, but no significant differences between NC16A-BP and non-NC16A-BP were observed. Furthermore, no obvious differences of ROS production were seen. Some of the differences in the titre and the ROS release may be attributed to the limited sample number, but these differences are not significant. These results indicate that the different clinical severities cannot be adequately explained by differences in the effector functions of the Fc fragment of the autoantibodies.
Hemidesmosomes are multiprotein complexes and are dynamic structures. [9, [18] [19] [20] We previously reported that BP-IgG depletes keratinocytes of COL17. [21] [22] [23] According to our previous study, the COL17-depletion was mediated after the internalization. [15, 24, 25] The COL17A1 gene expression data suggest that COL17 is depleted by BP-IgG stimulation via degradation and compensatory. The depletion of COL17 from the keratinocyte surface by the binding of autoantibodies depletes basal cells of COL17 and weakens the adhesive functions of hemidesmosomes. [9] The stimulation of NC16A-BP IgG significantly depletes COL17, but the stimulation of non-NC16A-BP IgG induced hardly any depletion in the present study. In addition, significantly fewer cells that had been stimulated by NC16A-BP IgG remained than those that had been stimulated by normal human IgG.
In contrast, stimulation with non-NC16A-BP IgG did not differ from stimulation with normal human IgG, in terms of adhesion strength. The detachment of NHEKs resulted from the depletion of COL17 induced specifically by NC16A-BP IgG. In conclusion, we speculate that the differences in clinical severity between NC16A-BP and non-NC16A-BP are related to the degree of COL17 depletion.
